PubMed article abstract display

Abstract

Background: Elevated antibody levels against Epstein-Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology.

Objectives: To examine effects of high-dose oral vitamin D₃ supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS.

Methods: Serum 25-hydroxyvitamin D₃ (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385-420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D₃ supplementation (20,000 IU/week) (NCT00785473).

Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D₃ supplementation did not affect antibodies against VCA, CMV or VZV.

Conclusion: The results indicate that high-dose oral vitamin D₃ supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.

Full text